Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients With Schizophrenia

Heidi Taipale; Antti Tanskanen; Jurjen J. Luykx; Marco Solmi; Stefan Leucht; Christoph U. Correll; Jari Tiihonen

Disclosures

Schizophr Bull. 2022;48(4):774-784. 

In This Article

Conclusions

Our results indicate that generally, the dose-response curves of antipsychotics followed a J- or U-shaped curve and relapse risk increased especially at low doses <0.6 DDDs/day or above ≥1.6 DDDs/day. Exceptions to this general rule were perphenazine and risperidone, with results indicating that the current standard doses by WHO are clearly too high for perphenazine and somewhat too high for risperidone for optimal maintenance treatment in relapse prevention. Olanzapine LAI at relatively high doses appeared to have markedly higher effectiveness in relapse prevention than any dose of any other antipsychotic. Finally, overall, LAIs had superior effectiveness for relapse prevention in this nationwide database study than oral antipsychotic formulations, excluding clozapine.

processing....